250 563

Cited 0 times in

The efficacy and safety of Montelukast sodium in the prevention of bronchopulmonary dysplasia.

DC Field Value Language
dc.contributor.authorKim, SB-
dc.contributor.authorLee, JH-
dc.contributor.authorLee, J-
dc.contributor.authorShin, SH-
dc.contributor.authorEun, HS-
dc.contributor.authorLee, SM-
dc.contributor.authorSohn, JA-
dc.contributor.authorKim, HS-
dc.contributor.authorChoi, BM-
dc.contributor.authorPark, MS-
dc.contributor.authorPark, KI-
dc.contributor.authorNamgung, R-
dc.date.accessioned2017-03-21T05:02:14Z-
dc.date.available2017-03-21T05:02:14Z-
dc.date.issued2015-
dc.identifier.issn1738-1061-
dc.identifier.urihttp://repository.ajou.ac.kr/handle/201003/13606-
dc.description.abstractPURPOSE: The purpose of this study was to evaluate the efficacy and safety of Montelukast sodium in the prevention of bronchopulmonarydysplasia (BPD).

METHODS: The Interventional study was designed as a multicenter, prospective, and randomized trial, with open labeled and parallel-experimental groups, 66 infants were enrolled and allocated to either the case group (n=30) or the control group (n=36) based on gestational age (GA). Infants in the case group were given Montelukast sodium (Singulair) based on their body weight (BW). Zero week was defined as the start time of the study.

RESULTS: The incidence of moderate to severe BPD was not different between the groups (case group: 13 of 30 [43.3%] vs. control group: 19 of 36 [52.8%], P=0.912). Additionally, secondary outcomes such as ventilation index, mean airway pressure and resort to systemic steroids were not significantly different. There were no serious adverse drug reactions in either group, and furthermore the rate of occurrence of mild drug related-events were not significantly different (case group: 10 of 42 [23.8%] vs. control group: 6 of 48 (15.8%), P=0.414).

CONCLUSION: Montelukast was not effective in reducing moderate or severe BPD. There were no significant adverse drug events associated with Montelukast treatment.
-
dc.language.isoen-
dc.titleThe efficacy and safety of Montelukast sodium in the prevention of bronchopulmonary dysplasia.-
dc.typeArticle-
dc.identifier.pmid26512261-
dc.identifier.urlhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4623454/-
dc.subject.keywordBroncopulmonary dysplasia-
dc.subject.keywordLeukotriene antagonists-
dc.subject.keywordMontelukast-
dc.subject.keywordPharmacokinetics-
dc.subject.keywordPremature infant-
dc.contributor.affiliatedAuthor이, 장훈-
dc.contributor.affiliatedAuthor박, 문성-
dc.type.localJournal Papers-
dc.identifier.doi10.3345/kjp.2015.58.9.347-
dc.citation.titleKorean journal of pediatrics-
dc.citation.volume58-
dc.citation.number9-
dc.citation.date2015-
dc.citation.startPage347-
dc.citation.endPage353-
dc.identifier.bibliographicCitationKorean journal of pediatrics, 58(9). : 347-353, 2015-
dc.identifier.eissn2092-7258-
dc.relation.journalidJ017381061-
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Pediatrics & Adolescent Medicine
Files in This Item:
26512261.pdfDownload

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse